Holen Sie sich die Stockscreener-App
12.10
3.15%
0.37
Handel nachbörslich:
12.10
Schlusskurs vom Vortag:
$11.73
Offen:
$11.66
24-Stunden-Volumen:
55,284
Relative Volume:
0.48
Marktkapitalisierung:
$3.65B
Einnahmen:
$306.77M
Nettoeinkommen (Verlust:
$-618.38M
KGV:
-6.1421
EPS:
-1.97
Netto-Cashflow:
$-343.00M
1W Leistung:
-0.90%
1M Leistung:
-1.94%
6M Leistung:
-10.37%
1J Leistung:
+34.44%
1-Tages-Spanne:
$11.36
$12.10
1-Wochen-Bereich:
$11.36
$13.14
52-Wochen-Spanne:
$8.90
$18.00
Alvotech Stock (ALVO) Company Profile
Vergleichen Sie ALVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ALVO | 12.10 | 3.65B | 306.77M | -618.38M | -343.00M | -1.97 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech Revenue Soars 800% to $339M, Achieves First Positive EBITDA | ALVO Stock News - StockTitan
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 - Yahoo Finance
ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology
Alvotech application for Simponi biosimilar accepted by EMA - MSN
Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times
European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire
Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com
Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN
Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha
Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times
Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks
Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Generics Bulletin | Insights on Off-Patent and Generic Medicines | Insights - Citeline
Alvotech Advances With EU Application Acceptance - TipRanks
Alvotech application for Prolia/Xgeva biosimilar accepted by EMA (NASDAQ:ALVO) - Seeking Alpha
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):